Walleye Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-40,200
| Closed | -$1.62M | – | 4716 |
|
|
2026
Q1 | $1.62M | Buy |
40,200
+35,400
| +738% | +$763K | 0.01% | 1640 |
|
|
2025
Q4 | $121K | Sell |
4,800
-8,000
| -63% | -$188K | ﹤0.01% | 3796 |
|
|
2025
Q3 | $290K | Sell |
12,800
-7,100
| -36% | -$166K | ﹤0.01% | 3033 |
|
|
2025
Q2 | $344K | Buy |
19,900
+10,400
| +109% | +$193K | ﹤0.01% | 2946 |
|
|
2025
Q1 | $208K | Buy |
9,500
+4,700
| +98% | +$130K | ﹤0.01% | 3232 |
|
|
2024
Q4 | $153K | Buy |
+4,800
| New | +$144K | ﹤0.01% | 3919 |
|
|
2024
Q3 | – | Sell |
-12,800
| Closed | -$491K | – | 5240 |
|
|
2024
Q2 | $491K | Sell |
12,800
-43,100
| -77% | -$1.95M | ﹤0.01% | 3536 |
|
|
2024
Q1 | $3.29M | Buy |
55,900
+45,900
| +459% | +$2.93M | 0.01% | 1622 |
|
|
2023
Q4 | $599K | Sell |
10,000
-30,700
| -75% | -$1.56M | ﹤0.01% | 2800 |
|
|
2023
Q3 | $1.55M | Buy |
40,700
+27,200
| +201% | +$1.19M | ﹤0.01% | 1921 |
|
|
2023
Q2 | $1.23M | Buy |
13,500
+7,400
| +121% | +$638K | ﹤0.01% | 1679 |
|
|
2023
Q1 | $402K | Sell |
6,100
-12,200
| -67% | -$704K | 0.01% | 1883 |
|
|
2022
Q4 | $946K | Buy |
18,300
+3,600
| +24% | +$191K | 0.02% | 1036 |
|
|
2022
Q3 | $1M | Buy |
+14,700
| New | +$870K | 0.02% | 971 |
|
|
2020
Q2 | – | Sell |
-9,500
| Closed | -$255K | – | 608 |
|
|
2020
Q1 | $255K | Buy |
+9,500
| New | +$337K | 0.06% | 377 |
|
Other funds holding APLS
Walleye Capital's APLS Position: Q2 2026 in Review
Walleye Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,290 shares — an estimated $132K sold.
Walleye Capital first reported a position in APLS in Q4 2021 and held it in 15 quarters. The position peaked at $12.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Walleye Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Capital sold 3,290 Apellis Pharmaceuticals shares in Q2 2026, an estimated $132K.
- Walleye Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 15 quarters.
- Walleye Capital's Apellis Pharmaceuticals position peaked at $12.6M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.